C-Type Natriuretic Peptide (CNP) (1-22), human
Based on 2 publication(s) in Google Scholar
C-Type Natriuretic Peptide (CNP) (1-22), human, a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor.
For research use only. We do not sell to patients.
- Purity: 98.84%
- CAS No.: 127869-51-6
- Formula: C93H157N27O28S3
- Molecular Weight:2197.60
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P1236
Atrial Natriuretic Peptide (ANP) (1-28), rat, mouse
-
HY-P3503
Vosoritide
-
HY-P0003
Nesiritide
-
HY-P5127
CNP-38
-
HY-15371
Forskolin
-
HY-P0201
Substance P
-
HY-15142
Doxorubicin hydrochloride
-
HY-D0842
BSA Protein
-
HY-P70578
Amphiregulin Protein, Human
-
HY-101474A
Zanubrutinib
-
HY-P70237
FSH Protein, Human (HEK293, Flag-His)
-
HY-P0012
Aviptadil
Publications Citing Use of MedChemExpress (MCE) C-Type Natriuretic Peptide (CNP) (1-22), human
More
Customer Validation & Images
-
Histological Imaging/Staining
-
Histological Imaging/Staining
-
In Vivo Efficacy Study
-
IF
-
RT-PCR
All Histamine Receptor Isoforms
More
Biological Activity
NPR-B[1]
C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) (0.01, 0.1, 1, 10, 100, 1000 nM) increases cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Dose (nM/kg) |
AUC0-∞ (pM·min/mL) |
MRT0-∞ (min) |
T1/2 (min) |
CLtot (mL/min/kg) |
Vdss (mL/kg) |
| 20 | 320±54 | 1.02±0.18 | 1.42±0.45 | 63.9±11.9 | 64.2±5.1 |
| Dose (nM/kg) |
Cmax (pM/mL) |
Tmax (min) |
AUC0-∞ (pM·min/mL) |
MRT0-∞ (min) |
T1/2 (min) |
BA (%) |
| 50 | 9.02±3.74 | 5.0±0.0 | 152±73 | 13.9±3.4 | 10.0±5.0 | 19±9 |
C-Type Natriuretic Peptide (CNP) (1-22) ( i.c.v.) in a dose of 2 nM induces an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 127869-51-6
-
Appearance Solid
-
Molecular Weight 2197.60
-
Formula C93H157N27O28S3
-
Color White to off-white
-
Sequence
Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys (Disulfide bridge: Cys6-Cys22)
-
Sequence Shortening
GLSKGCFGLKLDRIGSMSGLGC (Disulfide bridge: Cys6-Cys22)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
C-Type Natriuretic Peptide (CNP) (1-22), human purchased from MedChemExpress. Usage Cited in: Compos B Eng. 2025 May 15.
The heart of each group was mapped with the location of the ligation line and the infarct area. Hydrogel+CNP (C-Type Natriuretic Peptide)/Sema3A group: CNP/Sema3A-loaded hydrogel was applied, in which CNP was loaded at a concentration of 50 μg/mL, and specimens were harvested at 7, 14 and 28 days after intervention.
C-Type Natriuretic Peptide (CNP) (1-22), human purchased from MedChemExpress. Usage Cited in: Compos B Eng. 2025 May 15.
Enlarged image of Masson stain in local detail. Masson's trichrome staining further demonstrated apparent fibrosis formation and collagen deposition, accompanied by ventricular wall thinning in infarcted hearts. Hydrogel+CNP (C-Type Natriuretic Peptide)/Sema3A group: CNP/Sema3A-loaded hydrogel was applied, in which CNP was loaded at a concentration of 50 μg/mL, and specimens were harvested at 7, 14 and 28 days after intervention.
C-Type Natriuretic Peptide (CNP) (1-22), human purchased from MedChemExpress. Usage Cited in: Compos B Eng. 2025 May 15.
Cardiac function was recorded by M-mode echocardiography, ejection fraction calculation and fractional shortening calculation, LVEDV, LVESV calculation.Hydrogel+CNP (C-Type Natriuretic Peptide)/Sema3A group: CNP/Sema3A-loaded hydrogel was applied, in which CNP was loaded at a concentration of 50 μg/mL, and specimens were harvested at 7, 14 and 28 days after intervention.
C-Type Natriuretic Peptide (CNP) (1-22), human purchased from MedChemExpress. Usage Cited in: Compos B Eng. 2025 May 15.
α-SMA (green) and CD31 (red) representative immunofluorescence double staining. Hydrogel+CNP (C-Type Natriuretic Peptide)/Sema3A group: CNP/Sema3A-loaded hydrogel was applied, in which CNP was loaded at a concentration of 50 μg/mL, and specimens were harvested at 7, 14 and 28 days after intervention.
C-Type Natriuretic Peptide (CNP) (1-22), human purchased from MedChemExpress. Usage Cited in: Compos B Eng. 2025 May 15.
The expressions of CD68, CD4, CD11c and CD19 in Hydrogel group and CNP/Sema3A-loaded hydrogel group were recorded. Hydrogel+CNP (C-Type Natriuretic Peptide)/Sema3A group: CNP/Sema3A-loaded hydrogel was applied, in which CNP was loaded at a concentration of 50 μg/mL, and specimens were harvested at 7, 14 and 28 days after intervention.
-
Acta Biomater
The loading of C-type natriuretic peptides improved hemocompatibility and vascular regeneration of electrospun poly(ε-caprolactone) grafts. [Abstract]2022 Oct 1:151:304-316. PMID: 36002127
Solvent & Solubility
H2O : 50 mg/mL (22.75 mM; adjust pH to 3 with 0.5%CH3COOH)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
Rats[3]
Rats are preliminarily kindled with picrotoxin and convulsion is monitored. Rats then receive I.c.v. administration of C-Type Natriuretic Peptide (CNP) (1-22) (0.2, 1 or 2 nM in 2 mcl of 0.9% NaCI) under conditions of free behavior. Control animals receive an equal volume of saline. Within 10 min after the injections of the peptides, picrotoxin (1.5 mg/kg) is administered i.p. and the convulsion severity is evaluated as mentioned above[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (288 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Morozumi N, et al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680. [Content Brief]
[2]. Buckley MG, et al. Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy. Clin Sci (Lond). 2000 Nov;99(5):467-72. [Content Brief]
[3]. Mazarati AM, et al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.4550 mL | 2.2752 mL | 4.5504 mL | 11.3760 mL |
| 5 mM | 0.0910 mL | 0.4550 mL | 0.9101 mL | 2.2752 mL | |
| 10 mM | 0.0455 mL | 0.2275 mL | 0.4550 mL | 1.1376 mL | |
| 15 mM | 0.0303 mL | 0.1517 mL | 0.3034 mL | 0.7584 mL | |
| 20 mM | 0.0228 mL | 0.1138 mL | 0.2275 mL | 0.5688 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
C-Type Natriuretic Peptide (CNP) (1-22), human Related Classifications
HY-P1237 Related Classifications
Powered by Bioz